The study was withdrawn following strategic portfolio re-prioritization by Pfizer with zero actual enrollment, meaning no participants were recruited and no results are available despite the planned completion date of October 2023
How Can Patients Manage Weight While on Both Gabapentin and Semaglutide
Steroidal and non-steroidal FXR agonists (e.g., obeticholic acid and newer intestine-biased FXR agonists) consistently improve metabolic dysfunction-associated steatohepatitis histology and reduce liver fibrosis in phase 2 and 3 trials, but their effects on body weight, insulin resistance and systemic inflammatory markers are more modest than anticipated from preclinical studies [269,277,278]
Join our mailing list to receive the latest news and updates from our team
Strategies to minimize immunogenicity include careful peptide design to maintain similarity to natural sequences, appropriate formulation development, and monitoring for antibody formation during clinical development and post-market surveillance